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doi:10.1016/j.pedneo.2012.04.008Background: Pediatric glioblastoma is a malignant disease with an extremely poor clinical
outcome. Patients usually suffer from resistance to radiation therapy, so targeted drug treat-
ment may be a new possibility for glioblastoma therapy. Survivin is also overexpressed in glio-
blastoma. YM155, a novel small-molecule survivin inhibitor, has not been examined for its use
in glioblastoma therapy.
Methods: The human glioblastoma cell line M059K, which expresses normal DNA-dependent
protein kinase (DNA-PK) activity and is radiation-resistant, and M059J, which is deficient in
DNA-PK activity and radiation-sensitive, were used in the study. Cell viability, DNA fragmenta-
tion, and the expression of survivin and securin following YM155 treatment were examined
using MTT (methylthiazolyldiphenyl-tetrazolium) assay, ELISA assay, and Western blot analysis,
respectively.
Results: YM155 caused a concentration-dependent cytotoxic effect, inhibiting the cell viability
of both M059K and M059J cells by 70% after 48 hours of treatment with 50 nM YM155. The half-
maximal inhibitory concentration (IC50) was around 30e35 nM for both cell lines. Apoptosis
was determined to have occurred in both cell lines because immunoreactive signals from
the DNA fragments in the cytoplasm were increased 24 hours after treatment with 30 nMSurgical Intensive Care Unit, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung Yang Road,
ail.com (Y.T. Huang).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
200 P.C. Lai et alYM155. The expression of survivin and securin in the M059K cells was greater than that
measured in the M059J cells. Treatment with 30 nM YM155, for both 24 and 48 hours, signifi-
cantly suppressed the expression of survivin and securin in both cell lines.
Conclusion: The novel survivin inhibitor YM155 elicits potent cytotoxicity in glioblastoma cells
in vitro via DNA-PK-independent mechanisms. YM155 could be used as a new therapeutic agent
for the treatment of human glioblastomas.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Brain tumors are one of the most common solid neoplastic
disorders that present in children.1 The death of a pediatric
patient with a brain tumor, especially a high-grade glioma,
usually results from cancer.2,3 Glioblastoma demonstrates
the worse therapeutic response among high-grade gliomas,
with a very low 5-year survival rate despite aggressive
chemotherapy and/or radiation therapy.4e6 Thus, new
strategies for treating glioblastomas should be investigated.
Survivin, a member of the inhibitor of apoptosis protein
family, is overexpressed in human glioblastoma tissues.7
Studies have shown that the 3-year survival rate of glio-
blastoma tissues with positive nuclear survivin expression is
zero; thus, survivin may be a useful biomarker for pre-
dicting clinical prognosis in patients with glioblastoma.8
Treatments aimed at inhibiting survivin expression could
be a new strategy for the treatment of glioblastomas.9e13
However, specific survivin suppressants have not been
examined for use in glioblastoma treatments.
A small molecule, YM155 {1-(2-Methoxyethyl)-2-methyl-
4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho
[2,3-d] imidazolium bromide}, has been identified by high-
throughput screening as an inhibitor of the activity of the
survivin gene promoter.14 YM155, as a survivin suppressant,
has been shown to inhibit the progression of some
neoplasms in vitro and/or in vivo (e.g., prostate cancer14,15
and lung cancer).16,17 Until now, YM155 has not been
studied for its use in glioblastoma therapy. Therefore, we
conducted an in vitro study to evaluate the therapeutic
effects of YM155 in two glioblastoma cell lines: one cell line
that expresses normal DNA-dependent protein kinase (DNA-
PK) activity, and another cell line that is deficient in DNA-
PK activity. The former is resistant to radiation, whereas
the latter is sensitive to radiation.18 This study’s aim was to
demonstrate that YM155 exerts potent cytotoxicity through
survivin inhibition and induces apoptosis in both of these
glioblastoma cell lines.
2. Materials and Methods
2.1. Cell culture
Human glioblastoma cell lines M059J and M059K were
obtained from Dr. Shu Jun Chiu (Department of Life
Sciences, Tzu Chi University, Hualien, Taiwan). M059J and
M059K exhibit deficient DNA-PK and normal DNA-PK activi-
ties, respectively. The cells were cultured in F-12/Dulbecco’s modified Eagle medium in combination with
10% fetal bovine serum (FBS) and 1% penicillin plus
streptomycin.19
2.2. MTT cytotoxicity assay
For the cytotoxicity assay, 1.0 104 glioblastoma cells per
well were seeded onto 96-well plates. After overnight
incubation, the cells adhered to the plate. YM155 (Selleck,
Houston, TX, USA) at a concentration of 0e50 nM was dis-
solved in dimethyl sulfoxide (DMSO; J.T. Baker, Phillips-
burg, NJ, USA) and incubated for 48 hours. The MTT
(methylthiazolyldiphenyl-tetrazolium bromide; Sigma, St.
Louis, MO, USA) assay was then performed, using the
protocol described in a previous study.20
2.3. DNA fragmentation assay
The Cell Death Detection ELISAPLUS (Roche, Mannheim,
Germany) assay kit was used to differentiate apoptotic and
necrotic glioblastoma cells after treatment with YM155.
Twenty-four hours after drug treatment, both supernatants
of the cultured medium and the cytoplasmic fraction from
2.0 104 cells were collected in 24-well dishes. The optical
density (OD) value at 405 nm, which represents the extent
of DNA fragmentation, was measured.
2.4. Western blot analysis
After YM155 treatment, the expression levels of survivin
and securin in the glioblastoma cells were detected using
Western blot analysis. The procedures we followed were
described in our previous report.20 Primary antibodies,
including anti-survivin (#2808; Cell Signaling Technology,
Inc., Danvers, MA, USA) and anti-securin (ab3305; Abcam,
Cambridge, MA, USA), were used. The expression of
a-tubulin (anti-a-tubulin, sc-8305; Santa Cruz, CA, USA) was
used as the internal standard. The intensity of the immu-
noreactive proteins was calculated using NIH software
ImageJ V.1.40. The intensity ratio, which was calculated by
dividing the intensity of survivin or securin to that of
a-tubulin, was used to compare the effects of YM155
treatment.
2.5. Statistical analysis
Data are presented as the mean standard error of mean
(SEM) and were analyzed using the Student t test. In all
Figure 1 Cytotoxic effects of YM155 on glioblastoma cells.
The viability of (A) M059J (nZ 3) and (B) M059K (nZ 3) cells
was measured using an MTT assay 48 hours after treatment
with YM155. The viability ratio is the ratio of the optical
density value obtained from the drug-treated sample divided
by that of the control sample that was only treated with
phosphate-buffered saline.
Figure 2 DNA fragments in the culture medium and cyto-
plasm of M059J and M059K cells detected using ELISA. After
treatment with 30 nM YM155 for 24 hours, the supernatants of
both the culture medium and the cytoplasmic fraction of
2 104 (A) M059J (nZ 6) and (B) M059K (nZ 6) glioblastoma
cells were collected. Increased expression of DNA fragments in
the medium indicates necrosis due to membrane rupture,
while increased expression in the cytoplasm alone indicates
apoptosis. *** indicates p< 0.005.
YM155 in glioblastomas 201cases, p< 0.05 was considered statistically significant and
is labeled using an asterisk (*) in the figures. Double and
triple asterisks (** and ***) in the figures indicated p< 0.01
and p< 0.005, respectively.Table 1 Cell viability of glioblastoma cells 48 hours after
YM155 treatment.
Concentration
of YM155 (nM)
M059J (nZ 3) M059K (nZ 3)
0* 99.7 2.8 99.8 2.2
5 93.4 1.7 95.8 0.9
10 88.0 2.6 80.1 1.7
20 69.4 3.6 60.9 1.9
30 60.1 5.0 49.6 2.3
40 45.7 3.0 42.9 2.4
50 31.9 1.9 28.7 1.0
* Only DMSO was administered.3. Results3.1. Cytotoxic effects of YM155 on glioblastoma
cells
After 48 hours of treatment, YM155 elicited potent cyto-
toxicity in a concentration-dependent manner in both DNA-
PK-deficient M059J (Figure 1A) and DNA-PK-normal M059K
(Figure 1B) human glioblastoma cells. The half-maximal
inhibitory concentration (IC50) was about 30e35 nM
(Table 1). YM155 exerted significant cytotoxicity on both
cell lines when the concentrations were > 10 nM. The
viabilities of the M059J and M059K cells were not
Figure 3 Expression of survivin after YM155 treatment. Figures A, B and C, D refer to M059J (nZ 3) and M059K (nZ 3) cells,
respectively. (A, C) Representative Western blots of survivin expression that were examined 24 and 48 hours after treatment with
30 nM YM155. Expression of a-tubulin was used as the internal standard. (B, D) Quantitative comparisons of survivin expression.
** indicates p< 0.01; *** indicates p< 0.005.
202 P.C. Lai et alsignificantly different at each concentration of YM155
(5e50 nM; Table 1).
3.2. YM155 induces apoptosis in glioblastoma cells
To determine the characteristics of the cytotoxicity that
is mediated by YM155 in glioblastoma cells, a DNAFigure 4 Expression of securin after YM155 treatment. Figures
respectively. (A, C) Representative Western blots of securin express
nM YM155. Expression of a-tubulin was used as the internal stan
* indicates p< 0.05; ** indicates p< 0.01.fragmentation ELISA assay was carried out. Low basal levels
of DNA fragments bound to anti-histone plus anti-DNA
antibodies were detected in the culture medium of the
M059J and M059K cells 24 hours after treatment with 30 nM
YM155. A significantly large amount of cytoplasmic DNA
fragments was found after treating the M059J and M059K
cells with 30 nM YM155 in comparison with the controlA, B and C, D refer to M059J (nZ 3) and M059K (nZ 3) cells,
ion that were examined 24 and 48 hours after treatment with 30
dard. (B, D) Quantitative comparisons of securin expression.
YM155 in glioblastomas 203(Figure 2A and 2B). These results indicated that YM155
induces apoptosis in M059J and M059K glioblastoma cells.
3.3. Expression of survivin in glioblastoma cells
after YM155 treatment
As shown in Figure 3A and 3B, survivin expression in the
M059J cells was inhibited by about 80% at 24 hours after
treatment with 30 nM YM155, and almost the complete
inhibition (96.6%) of survivin expression was noted 48 hours
after treatment. Figure 3C shows that the expression of
immunoreactive survivin in M059K cells was more abundant
(1.56-fold higher, pZ 0.01) than that measured in M059J
cells. Survivin expression in M059K cells was also signifi-
cantly inhibited 24 hours after treatment with 30 nM
YM155, and > 80% inhibition was noted 48 hours later
(Figure 3C and 3D).
3.4. Expression of securin in glioblastoma cells
after YM155 treatment
Comparisons of the immunoreactive signals between the
two glioblastoma cell lines shows that securin was much
more strongly expressed in M059K cells (2.56-fold higher,
pZ 0.01) than M059J cells (Figure 4A and 4C). Securin
expression in the M059J cells (Figure 4A and 4B) and M059J
cells (Figure 4C and 4D) was significantly inhibited at 24 and
48 hours after treatment with 30 nM YM155.
4. Discussion
DNA-PK is a nuclear protein kinase that consists of a cata-
lytic subunit (DNA-PKcs) and a heterodimeric DNA targeting
subunit (Ku).21 DNA-PK is directly activated by double-
stranded DNA after exposure to ionizing radiation (IR),22
and it plays an important role in the repair of double-
stranded breaks via nonhomologous end-joining (NHEJ)
and V(D)J recombination.23 Cells that are deficient in DNA-
PK activity are extremely sensitive to IR.24 Conversely,
increased expression or activity of DNA-PK promotes cancer
cell resistance to chemotherapeutic agents or IR.25,26 Thus,
the M059K human glioblastoma cell line with normal DNA-
PK may be a good cell model for investigating new treat-
ment strategies against radiation-resistant glioblastoma.
Our results show that the novel survivin inhibitor YM155
elicits cytotoxicity in the glioblastoma cell lines M059K and
M059J, indicating that DNA-PK is not involved in survivin
inhibition-induced apoptosis of glioblastoma cells. Capalbo
et al described the interaction between nuclear survivin
and DNA-PKs following exposure to irradiation, demon-
strating that survivin knockdown by RNAi impairs the repair
of double-stranded DNA breaks.27 Survivin-depleted cells
also present with decreased DNA-PK activities.27 This
evidence explains why survivin expression in radiation-
resistant M059K cells was greater than that measured in
radiation-sensitive M059J cells in this study. This is consis-
tent with the observation that survivin mediates radio-
resistance in cancer cells.28,29 Survivin is undetectable in
normally differentiated human adult tissues.30 Thus, the
targeting of survivin inhibition may not influence thefunctioning of normal cells. Knockdown of survivin by shRNA
delays the growth of glioblastoma xenografts in nude
mice.31 However, the clinical applications of genetic
knockdowns may not be feasible in the near future. A few
phase I/II clinical trials on the use of YM155 in cancer
therapies have already been reported, and these treat-
ments were well tolerated by patients with minimal
adverse effects such as fatigue, nausea, and pyrexia.32e34
Thus, YM155 may offer a new hope for glioblastoma
patients, including those with radiation resistance.
Human securin is identical to the product of PTTG
(pituitary tumor-derived transforming gene), and the
overexpression of securin has been observed in several
human cancers other than pituitary tumors.35e37 The
securin that is expressed in the nuclei was originally found
to be an inhibitor of premature sister chromatid separation
and a potential activator of transcription, but recently it
has also been found to mediate tumor invasiveness and
recurrence.38 Until now, there have been no studies that
have investigated the expression of securin in human glio-
blastoma cells and tissues, and our results provide the first
results. In our previous report, concomitantly decreased
expression of survivin and securin in bladder cancer cells
was noted after TrkB antibody treatment.39 Chao and Liu
have also demonstrated that the transfection of survivin
siRNA significantly induces apoptosis and decreases the
levels of survivin and securin proteins in A549 cells.40 Thus,
the decreased expression of securin and elevated apoptosis
following YM155 treatment observed in our study is
consistent with previous studies. Furthermore, Chen et al
reported that securin mediates radiosensitivity.41 Thus, the
higher expression level of securin that was observed in
M059K cells in comparison with M059J cells may at least
partly explain why M059K cells exhibit radiation resistance.
In conclusion, survivin inhibition by YM155 elicits potent
cytotoxicity in human glioblastoma cells via DNA-PK-
independent mechanisms. YM155 could be used as a new
therapeutic drug for treating glioblastomas, including those
that are resistant to radiation.Acknowledgments
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